HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Rook, G.A.W. Articles by Ustianowski, A. Search for Related Content PubMed PubMed Citation Articles by Rook, G.A.W. Articles by Ustianowski, A.

M. tuberculosis: immunology and vaccination

Dept of Bacteriology, Royal Free and University College London Medical School, Windeyer Institute of Medical Sciences, London, UK

CORRESPONDENCE: G.A.W. Rook, Dept of Bacteriology, Royal Free and University College London Medical School, Windeyer Institute of Medical Sciences, 46 Cleveland Street, London, UK.

Keywords: cytokines, endocrinology, immunology, immunotherapy, macrophages, vaccines

Received: June 20, 2000
Accepted June 27, 2000

Abstract

Tuberculosis is increasing. Current treatment regimens require at least 6 months, because latent or stationary phase organisms are difficult to kill. Such regimens do not achieve full compliance, and "directly observed therapy short course" (DOTS) is having less impact than expected. This worrying situation is aggravated by coinfection with human immunodeficiency virus (HIV), and by the increase in drug-resistant strains.

We need new insights that lead to more rapid therapies and immunotherapies, and more reliable vaccines.

Recent insights have come from: understanding of the relationship between Mycobacterium tuberculosis and macrophages; the multiple T cell types that recognise mycobacterial peptides, lipids and glycolipids; the critical role of interferon- (IFN) and interleukin-12 (IL-12) in human mycobacterial infection revealed by genetically defective children; quantitation of the presence and importance of Th2 lymphocyte activation in human tuberculosis; the role of local conversion of inactive cortisone to active cortisol in the lesions; the recognition that some effective prophylactic vaccines also work as immumotherapeutics whereas others do not. In the longer term the recent sequencing of the M. tuberculosis genome will lead to further advances.

In the short term, effective immunotherapy remains the most accessible breakthrough in the management of tuberculosis. The types of practical advance that will result from sequencing the genome are discussed speculatively, but cannot yet be predicted with certainty.